Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
PACB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $2.72
Previous CloseN/A
Volume8.28M
Average Volume (3M)7.97M
Market Cap
$369.46M
Enterprise Value$756.39M
Total Cash (Recent Filing)$314.74M
Total Debt (Recent Filing)$699.22M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 10, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding300,370,600
10 Day Avg. Volume9,227,838
30 Day Avg. Volume7,974,885
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.05
Enterprise Value/Revenue4.85
Enterprise Value/Gross Profit-2.30
Enterprise Value/Ebitda-6.75
Forecast
1Y Price Target
$1.99Price Target Upside61.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
EarningsPacific Biosciences reported strong 2Q results that came in ahead of street expectations, driven by strong instrument placements despite a challenging macroenvironment.
Market ExpansionPacBio's systems are gaining clinical uptake, with a third of Revios shipped to labs.
Product DevelopmentThe development of multi-use SMRT cells is expected to lower the cost per genome for customers and improve PACB's gross margin.
Bears Say
GuidanceThe company's guidance range has been narrowed, but policy uncertainty still weighs on near-term visibility.
Policy UncertaintyThe new product cycles underway inherently limit near-term P&L visibility, particularly against a challenging macro backdrop, NIH funding uncertainty, and an evolving tariff rate regime.
Revenue GuidancePACB decreased the lower end of its 2025 revenue guidance range due to U.S./China tariffs and NIH budget reductions.
Pacific Biosciences News
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $0.85 and its highest was $2.72 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is $369.46M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Nov 10, 2025 which is in 86 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.03.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.15.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 300,370,600 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Currently, no hedge funds are holding shares in PACB
Pacific Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.99 (61.79% Upside)
$1.99 (61.79% Upside)
Blogger Sentiment
Bearish
PACB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 180.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.88%
12-Months-Change
Fundamentals
Return on Equity
-189.52%
Trailing 12-Months
Asset Growth
-45.31%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences (PACB) is a biotechnology company specializing in the development and commercialization of advanced sequencing technologies for genomic research. Founded in 2004 and headquartered in Menlo Park, California, PACB focuses on providing high-throughput, long-read sequencing solutions that enable researchers to analyze complex genomes with unprecedented accuracy. Its core products include the Sequel II and Sequel IIe Systems, which are designed for a wide range of applications, from basic research to clinical genomics, and support various fields such as agriculture, human health, and environmental science.
PACB Company Deck
PACB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted PacBio's strong international revenue growth, successful adoption of new technologies like SPRQ chemistry, and expansion into clinical applications. However, challenges persist in the U.S. market due to funding constraints and macroeconomic uncertainties. Overall, the positive aspects, such as international expansion and innovation adoption, outweigh the challenges faced domestically.View all PACB earnings summariesPACB Stock 12 Month Forecast
Average Price Target
$1.99
▲(61.79% Upside)
Technical Analysis
Ownership Overview
2.92% Insiders
9.63% Mutual Funds
0.89% Other Institutional Investors
64.80% Public Companies and Individual Investors